NASDAQ:TBPH

Theravance Biopharma Competitors

$18.87

+0.33 (+1.78 %)

(As of 05/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$18.09

▼

$18.99

50-Day Range

$18.54

▼

$22.46

52-Week Range

$14.48

▼

$28.98

Volume473,759 shs

Average Volume333,855 shs

Market Capitalization$1.23 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.94

Theravance Biopharma (NASDAQ:TBPH) Vs. GLPG, IMAB, SAGE, BHVN, SDGR, and LEGN

Should you be buying TBPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Theravance Biopharma, including Galapagos (GLPG), I-Mab (IMAB), Sage Therapeutics (SAGE), Biohaven Pharmaceutical (BHVN), Schrödinger (SDGR), and Legend Biotech (LEGN).

Theravance Biopharma vs. Galapagos Stock

Theravance Biopharma (NASDAQ:TBPH) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Risk and Volatility

Theravance Biopharma has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Institutional & Insider Ownership

80.4% of Theravance Biopharma shares are held by institutional investors. Comparatively, 11.2% of Galapagos shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by insiders. Comparatively, 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Theravance Biopharma and Galapagos' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$73.41 million	16.78	$-236,460,000.00	($4.25)	-4.44
Galapagos	$1.00 billion	4.84	$167.83 million	$5.46	13.58

Galapagos has higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theravance Biopharma and Galapagos' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	-345.16%	N/A	-51.60%
Galapagos	-70.67%	-11.78%	-5.58%

Analyst Ratings

This is a summary of recent recommendations for Theravance Biopharma and Galapagos, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	0	8	0	3.00
Galapagos	2	10	6	0	2.22

Theravance Biopharma presently has a consensus price target of $33.1429, suggesting a potential upside of 75.64%. Galapagos has a consensus price target of $143.8182, suggesting a potential upside of 93.98%. Given Galapagos' higher probable upside, analysts plainly believe Galapagos is more favorable than Theravance Biopharma.

Summary

Theravance Biopharma beats Galapagos on 8 of the 14 factors compared between the two stocks.

Theravance Biopharma vs. I-Mab Stock

I-Mab (NASDAQ:IMAB) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Analyst Ratings

This is a breakdown of current recommendations for I-Mab and Theravance Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0	0	4	0	3.00
Theravance Biopharma	0	0	8	0	3.00

I-Mab presently has a consensus price target of $70.00, suggesting a potential upside of 12.78%. Theravance Biopharma has a consensus price target of $33.1429, suggesting a potential upside of 75.64%. Given Theravance Biopharma's higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than I-Mab.

Insider & Institutional Ownership

16.6% of I-Mab shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares I-Mab and Theravance Biopharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$4.31 million	1,042.73	$-208,560,000.00	($28.90)	-2.15
Theravance Biopharma	$73.41 million	16.78	$-236,460,000.00	($4.25)	-4.44

I-Mab has higher earnings, but lower revenue than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares I-Mab and Theravance Biopharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Theravance Biopharma	-345.16%	N/A	-51.60%

Summary

Theravance Biopharma beats I-Mab on 6 of the 11 factors compared between the two stocks.

Theravance Biopharma vs. Sage Therapeutics Stock

Theravance Biopharma (NASDAQ:TBPH) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Theravance Biopharma and Sage Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	0	8	0	3.00
Sage Therapeutics	0	7	8	0	2.53

Theravance Biopharma presently has a consensus price target of $33.1429, indicating a potential upside of 75.64%. Sage Therapeutics has a consensus price target of $89.8667, indicating a potential upside of 21.64%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Theravance Biopharma is more favorable than Sage Therapeutics.

Profitability

This table compares Theravance Biopharma and Sage Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	-345.16%	N/A	-51.60%
Sage Therapeutics	-7,706.84%	-63.81%	-56.64%

Risk and Volatility

Theravance Biopharma has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500.

Institutional and Insider Ownership

80.4% of Theravance Biopharma shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Theravance Biopharma and Sage Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$73.41 million	16.78	$-236,460,000.00	($4.25)	-4.44
Sage Therapeutics	$6.87 million	628.89	$-680,240,000.00	($13.38)	-5.52

Theravance Biopharma has higher revenue and earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Theravance Biopharma beats Sage Therapeutics on 11 of the 13 factors compared between the two stocks.

Theravance Biopharma vs. Biohaven Pharmaceutical Stock

Biohaven Pharmaceutical (NYSE:BHVN) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Risk and Volatility

Biohaven Pharmaceutical has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Earnings and Valuation

This table compares Biohaven Pharmaceutical and Theravance Biopharma's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven Pharmaceutical	N/A	N/A	$-528,800,000.00	($10.91)	-6.26
Theravance Biopharma	$73.41 million	16.78	$-236,460,000.00	($4.25)	-4.44

Theravance Biopharma has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Biohaven Pharmaceutical and Theravance Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven Pharmaceutical	0	1	10	0	2.91
Theravance Biopharma	0	0	8	0	3.00

Biohaven Pharmaceutical presently has a consensus target price of $99.50, indicating a potential upside of 45.74%. Theravance Biopharma has a consensus target price of $33.1429, indicating a potential upside of 75.64%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Theravance Biopharma is more favorable than Biohaven Pharmaceutical.

Profitability

This table compares Biohaven Pharmaceutical and Theravance Biopharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biohaven Pharmaceutical	N/A	-1,091.41%	-120.85%
Theravance Biopharma	-345.16%	N/A	-51.60%

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by insiders. Comparatively, 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Theravance Biopharma beats Biohaven Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Theravance Biopharma vs. Schrödinger Stock

Theravance Biopharma (NASDAQ:TBPH) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Insider and Institutional Ownership

80.4% of Theravance Biopharma shares are held by institutional investors. Comparatively, 41.3% of Schrödinger shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Theravance Biopharma and Schrödinger's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	-345.16%	N/A	-51.60%
Schrödinger	-19.92%	-7.25%	-5.33%

Analyst Ratings

This is a summary of recent recommendations and price targets for Theravance Biopharma and Schrödinger, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	0	8	0	3.00
Schrödinger	0	1	3	0	2.75

Theravance Biopharma presently has a consensus price target of $33.1429, indicating a potential upside of 75.64%. Schrödinger has a consensus price target of $84.00, indicating a potential upside of 40.75%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than Schrödinger.

Valuation & Earnings

This table compares Theravance Biopharma and Schrödinger's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$73.41 million	16.78	$-236,460,000.00	($4.25)	-4.44
Schrödinger	$85.54 million	48.85	$-24,570,000.00	N/A	N/A

Schrödinger has higher revenue and earnings than Theravance Biopharma.

Summary

Theravance Biopharma beats Schrödinger on 6 of the 11 factors compared between the two stocks.

Theravance Biopharma vs. Legend Biotech Stock

Legend Biotech (NASDAQ:LEGN) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

18.9% of Legend Biotech shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 5.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Legend Biotech and Theravance Biopharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-543.73%	-205.60%	-43.03%
Theravance Biopharma	-345.16%	N/A	-51.60%

Earnings & Valuation

This table compares Legend Biotech and Theravance Biopharma's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$64.39 million	62.69	$-132,970,000.00	N/A	N/A
Theravance Biopharma	$73.41 million	16.78	$-236,460,000.00	($4.25)	-4.44

Legend Biotech has higher earnings, but lower revenue than Theravance Biopharma.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Legend Biotech and Theravance Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	0	0	3	0	3.00
Theravance Biopharma	0	0	8	0	3.00

Legend Biotech presently has a consensus price target of $49.00, suggesting a potential upside of 61.45%. Theravance Biopharma has a consensus price target of $33.1429, suggesting a potential upside of 75.64%. Given Theravance Biopharma's higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Legend Biotech.

Summary

Theravance Biopharma beats Legend Biotech on 7 of the 10 factors compared between the two stocks.